Top Pick of the Day: NBIX

Neurorine Biosciences Inc. (NBIX) announced receiving FDA approval for its drug Ingrezza, which is designed for treating  tardive dyskinesia, a side effect of antipsychotic medications characterized by uncontrolled movements of the face and body. The drug is also the first treatment to be approved for the irreversible disorder, which occurs in 5 percent to 8 percent of patients taking antipsychotic drugs. It is also the first commercial product for Neurorine.
The company stock jumped over 23 percent in the pre-market trading session. The treatment is expected to be in the market by May this year. Its net price will likely be  between $20,000 to $60,000 per year, depending on the required dosage.

Focus Ticker: NOVN

Novan (NOVN) stock skyrocketed as the company reported  positive topline results from the Company’s Phase 2 clinical trial with SB208. The company reported that 80.6% of patients treated with SB208 4% and 74.2% treated with SB208 16% achieved negative fungal culture at day 14 versus 45.5% of patients treated with vehicle. The results were obtained from  the primary efficacy analysis of patients with evaluable culture results. SB208 is a topical, silicone based antifungal gel under development for the treatment of infections caused by dermatophytes such as Trichophyton rubrum, superficial cutaneous fungal infections of the skin and nails, including tinea pedis and onychomycosis.
The company stock rose over 63 percent in the pre-market session.

Sector News

AVEO Pharmaceuticals (AVEO) is scheduled to be listed on the Nasdaq Capital Market on April 13th. The company is currently  working to regain compliance with the $1 minimum bid price requirement. It has until October 9 to address the issue or face possible delisting.

Protalix BioTherapeutics (PLX) reported positive results from a 16-subject Phase 2 clinical trial evaluating AIR DNase (alidornase alfa) in cystic fibrosis (CF) patients previously treated with Pulmozyme (dornase alfa). Preliminary data showed patients treated with alidornase alfa experienced a clinically meaningful improvement in lung function as measured by the percent increase in percent predicted forced expiratory volume in one second (ppFEV1) of 3.4 points from baseline.